Key result
Longer statin duration linked to higher fasting insulin, HOMA-IR, and HbA1c in Hispanic T2D adults.
Why the study?
Statins may influence glucose metabolism, but associations between dose or potency and increased insulin resistance and glycemia remain inconsistent.
Does statin duration and potency increase insulin resistance and glycemic markers in Hispanic adults with type 2 diabetes?
Cross-Sectional (n=252)
Does statin duration and potency increase insulin resistance and glycemic markers in Hispanic adults with type 2 diabetes?
Effect estimate: β=0.028
p-value: p=0.004
In Hispanic adults with type 2 diabetes, longer cumulative statin exposure is associated with higher insulin resistance and HbA1c levels.
May worsen glycemic markers with longer statin use in Hispanic T2D adults; hypothesis-generating, needs prospective confirmation.
Introduction and Objective: Statins are widely prescribed for cardiovascular risk reduction, but they may influence glucose metabolism. Prior studies report increased insulin resistance (IR) and glycemia with statins, though dose and potency associations are inconsistent. We investigated associations of statin duration and potency with fasting insulin, HOMA-IR, and HbA1c in Hispanic adults with type 2 diabetes (T2D). Methods: In a cross-sectional study of 252 Hispanic adults with T2D, aged 40 to 65 years, fasting insulin, HOMA-IR, and HbA1c were assessed. Multivariable linear regression evaluated associations of statin duration (years) and potency (high vs low/moderate) with outcomes, adjusting for age, sex, education, BMI, smoking, alcohol use, and metformin duration. Fasting insulin and HOMA-IR were log-transformed due to skewed distributions. Results: Longer statin duration (N=250) was associated with higher log-transformed fasting insulin (β=0.028, SE=0.009, p=0.004), log-transformed HOMA-IR (β=0.029, SE=0.011, p=0.009), and HbA1c (β=0.047, SE=0.023, p=0.046). High-potency statins (N=231) were significantly associated with higher fasting insulin in untransformed analysis (β=7.02, SE=3.47, p=0.044) but not with log-transformed insulin, HOMA-IR, or HbA1c. Conclusion: In Hispanic adults with T2D, longer statin use is associated with higher insulin, insulin resistance, and HbA1c, independent of covariates. Associations with high-potency statins were strongest for fasting insulin but may be influenced by skewed values. These findings highlight the potential metabolic impact of cumulative statin exposure and support further longitudinal studies. Disclosure O.M. Andriankaja: None. C. Brown: None. M.M. Viana Miguel: None. Y. Teixeira das Gracas: None. L.M. Shaddox: None. Funding University of Kentucky, Barnstable Brown Diabetes and Obesity Center and The Bill Gatton Foundation: Breakthrough Ideas Grant (BIG) Program
No takes yet. Share an insight, caveat, or question.
ANDRIANKAJA et al. (2026) conducted a cross-sectional in Type 2 diabetes (n=252). Statin duration and potency vs. Low/moderate potency was evaluated on Log-transformed fasting insulin (β=0.028, p=0.004). Longer statin duration was significantly associated with higher log-transformed fasting insulin (β=0.028, p=0.004), HOMA-IR, and HbA1c in Hispanic adults with type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: